• growth of Delta-8 products, and impacts on sales of other CBD and cannabis products
• regulatory developments, and the potential impact on the regulation of CBD on a federal level
• product innovation in the US, and new formats which are working with consumers
• the future of the consumer CBD and cannabis sectors as the products go mainstream

• What is the current funding climate for the cannabis sector?
• What will drive the next investment opportunities in cannabis?
• How have IPOs in Europe changed the narrative for capital raising?
• How will the European market develop differently to North America?
• Where does the sector go from here as an asset class?

• Looking at the rising interest between vaping and CBD products. Is there scope for this in the future?
• Linking analysis and testing to launch successful NPD
• Meeting the highest standards in quality product development to ensure consumer trust and safety

Reserved for Sponsor

• Looking at the potential of cannabis beyond FMCG and medical to identify areas of growth
• Understanding best use of practice to monetise, industrialise the plant to achieve greater success
• Putting people, planet and product at the core of the cannabis industry to create a fruitful industry that ticks all of the boxes
• Taking inspiration from successful cannabis production and routes to market to innovate and succeed
• Identifying the potential in hemp to create profitable products and promote innovation in the hemp and CBD space

• Will Europe be an easy entry market once North America irons out its legislations?
• What can we expect from Europe in the future and how soon will we see a better access to market?

• The expansion of medical cannabis access in European markets after progress in North America
• Analyzing what works and what doesn’t in existing markets to improve accessibility in Europe
• What is the future opportunity of cannabis in the EU based on its evolution in North America

• The buzz around consumer brands in the CBD space has continued to grow, but how does the current branded landscape deliver?
• What will excite consumers and how can we stoke demand for consumer goods to build value for the rest of the industry?
• How can we leverage expertise and lessons from outside of the industry to build compelling brand within the CBD industry?

• • Reliable CBD
  • GMP certified
  • outstanding quality and availability standards

• Science-based vs. survey-based regulation: what is the tipping point for governments to act
• How to avoid reinventing the wheel: sustaining a responsible industry
• Opportunities and impediments to legalization in potentially lucrative geographies (e.g., India)
• Synergies with the nicotine industry – eye on M&A

• Looking at current regulations and their implications for the CBD markets
• Understanding potential hurdles and discovering methods of best practice
• Predicting the future of CBD to understand where the market is headed and what needs to be done to protect your brand

• Creating transparency in the industry to move away from stigma and towards a category that delivers its promises
• Supplying evidence-based studies on how cannabis works on improving people’s lives
• Setting product transparency through innovative technologies to educate consumers (data and dosing)
• Protecting your business through a strong sustainability message and strategy

Looking at the major challenges for social equity applicants and licensees, the need for access to capital, and how states need to fund social equity programs from the outset rather than wait for cannabis revenues to start rolling in.

• Why is social equity so important for a successful industry and in which areas are we lacking focus?
• Promoting businesses in cannabis for the growth of a responsible and legitimate industry that works for favourable social, economic and legal environments
• Fighting stigmas associated with cannabis to help the category thrive in a modern-day market
• What can governments do to promote social equity before the onset of legal markets? What can businesses do?
• Creating opportunity in new markets to encourage cannabis product acceptance, focus on equity and industry growth
• Understanding the importance of consumer desires to support companies that fill industry needs

• What the regulations look like for new entry product to the UK market
• Navigating the rules and regulations to comply with FSA expectations
• Navigating around industry regulations to forge ahead with minimal diversion

• • What’s different now vs pre-covid and what long-lasting effects can we see through covid change?
  • Where is the future of brick-and-mortar retail and how will this tie in with the Cannabis experience?
  • Delivery and Technology – how do we find the balance?
  • How can we leverage digital channels to drive cannabis growth?
  • What are the new opportunities to be found in e-retail for greater category growth and accessibility?
  • How can we target consumers through social media to reach new customers and encourage brand loyalty?
  • What can we see in terms of innovation and digitalisation to approach customers and encourage higher purchase rates?
  • What are the key concepts to consider when looking at avenues of collaboration for strong cannabis brand messaging?

• Has the CBD industry neglected the wants and needs of the consumer?
• What do CBD users want and are suppliers meeting their needs and expectations?
• Are purpose driven brands driving growth across a variety of sectors?
• How much should sustainability and purpose play a role in building the industry?
• How effectively are brands communicating the CBD message and are we seeing changes in branding and marketing as a result?

• • Navigating the legal landscape to ensure your business is equipped for the CBD market
  • Understanding the highlights and challenges on a state by state basis in the US
  • Looking into the FDA’s process in creating a regulatory framework for ingestible CBD and hemp extract products to understand how much progress we currently see
  • Filtering through the spectrum of confusion caused by FDA delays to support states and understand how and why they are taking matters into their own hands